29
CYRAMZA (Ramucirumab) is a human IgG1 monoclonal antibody that has been approved by the FDA for the treatment of some types of cancer. CYRAMZA specifically binds to the extracellular domain of the human vascular endothelial growth factor receptor 2 (VEGFR2), which is important for promoting the growth and spread of cancer cells. As a result, it can be used to help reduce tumor size, prevent the spread of cancer, and in some cases, prolong survival.